10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||||||||||||
| |||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
REGENERON PHARMACEUTICALS, INC. | |||
Ticker: REGN Fiscal Year: 2016 | |||
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME | |||
Period Ending Dec 31, 2016 10-K (Filed: Feb 9, 2017) | |||
| (In Thousands) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | |
| Income Statement [Abstract] | |||
| Revenues: | |||
| Net product sales | $ 3,338,390 | 2,689,478 | 1,750,762 |
| Sanofi collaboration revenue | 658,665 | 758,873 | 541,299 |
| Bayer collaboration revenue | 744,270 | 580,488 | 495,555 |
| Other revenue | 119,102 | 74,889 | 31,941 |
| Total revenues | 4,860,427 | 4,103,728 | 2,819,557 |
| Expenses: | |||
| Research and development | 2,052,295 | 1,620,577 | 1,271,353 |
| Selling, general, and administrative | 1,177,697 | 838,526 | 519,267 |
| Cost of goods sold | 194,624 | 241,702 | 129,030 |
| Cost of collaboration and contract manufacturing | 105,070 | 151,007 | 75,988 |
| Total expenses | 3,529,686 | 2,851,812 | 1,995,638 |
| Income from operations | 1,330,741 | 1,251,916 | 823,919 |
| Other income (expense): | |||
| Other income (expense), net | 6,269 | (12,578) | (25,312) |
| Interest expense | (7,195) | (14,241) | (37,372) |
| Total other income (expense) | (926) | (26,819) | (62,684) |
| Income before income taxes | 1,329,815 | 1,225,097 | 761,235 |
| Income tax expense | (434,293) | (589,041) | (423,109) |
| Net income | 895,522 | 636,056 | 338,126 |
| Net income per share - basic | 8.55 | 6.17 | 3.36 |
| Net income per share - diluted | 7.70 | 5.52 | 2.98 |
| Weighted average shares outstanding - basic | 104,719 | 103,061 | 100,612 |
| Weighted average shares outstanding - diluted | 116,367 | 115,230 | 113,413 |
| Statements of Comprehensive Income | |||
| Net income | 895,522 | 636,056 | 338,126 |
| Other comprehensive income (loss): | |||
| Unrealized (loss) gain on marketable securities, net of tax | (21,412) | (43,679) | 53,439 |
| Comprehensive income | 874,110 | 592,377 | 391,565 |
| External Links | |
| REGENERON PHARMACEUTICALS, INC. (REGN) Fiscal Year 2016 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |